XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2022
Jan. 01, 2022
Apr. 30, 2018
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Loss Contingencies [Line Items]              
Operating leases, rent expense       $ 47,000 $ 70,000 $ 100,000 $ 200,000
Remaining lease term       2 years 3 months 18 days   2 years 3 months 18 days  
Incremental borrowing rate used to determine operating lease liability percentage           6.50%  
Teva Agreement              
Loss Contingencies [Line Items]              
Payment upon achievement of certain clinical and commercial milestones     $ 135,000,000.0        
Asset transfer and license agreement, termination period after written notice           120 days  
Asset transfer and license agreement, termination period notice of breach           60 days  
Asset transfer and license agreement termination notice period if bankruptcy petition filed           60 days  
Teva Agreement | Research and Development Expenses              
Loss Contingencies [Line Items]              
Milestone payments       $ 0 $ 0 $ 0 $ 0
Teva Agreement | Teva's GlycoPEGylated FGF21 Program              
Loss Contingencies [Line Items]              
Payment upon achievement of certain clinical and commercial milestones     67,500,000        
Teva Agreement | Teva's Development Program              
Loss Contingencies [Line Items]              
Payment upon achievement of certain clinical and commercial milestones     $ 67,500,000        
San Francisco Office              
Loss Contingencies [Line Items]              
Operating lease expiration month and year 2025-01 2023-01